Auayporn Nademanee

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred Rademaker et al. · Blood · 2013 · 953 citations

Medicine, Hematology, Oncology +14

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee et al. · Blood · 2009 · 780 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff et al. · Journal of Clinical Oncology · 2009 · 673 citations

Medicine, Hematology, Immunology +17

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study

Liton Francisco, Andrea Carter, Can-Lan Sun et al. · Blood · 2007 · 537 citations · Full text

Medicine, Hematology, Stem Cell Transplantation +16